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The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing
highly prevalent diseases and often severe or fatal in humans and animals. No licensed specific drugs are available to
prevent their infection. Different host receptors for cellular entry, poorly conserved structural proteins (antigens), and
the high mutation and recombination rates of CoVs pose a significant problem in the development of wide-spectrum
anti-CoV drugs and vaccines. CoV main proteases (M
pros), which are key enzymes in viral gene expression and
replication, were revealed to share a highly conservative substrate-recognition pocket by comparison of four crystal
structures and a homology model representing all three genetic clusters of the genus Coronavirus. This conclusion was
further supported by enzyme activity assays. Mechanism-based irreversible inhibitors were designed, based on this
conserved structural region, and a uniform inhibition mechanism was elucidated from the structures of M
pro-inhibitor
complexes from severe acute respiratory syndrome-CoV and porcine transmissible gastroenteritis virus. A structure-
assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV M
pros, potent
antiviral activity, and extremely low cellular toxicity in cell-based assays. Further modification could rapidly lead to the
discovery of a single agent with clinical potential against existing and possible future emerging CoV-related diseases.
Citation: Yang H, Xie W, Xue X, Yang K, Ma J, et al. (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3(10): e324.
Introduction
The genus Coronavirus belongs to the plus-strand RNA virus
family of the Coronaviridae and currently contains about 25
species that are classiﬁed into three groups according to their
genetic and serological relationships [1–4]. Coronaviruses
(CoVs) infect humans and multiple species of animals,
causing a variety of highly prevalent and severe diseases
[1,5]. For example, human coronavirus (HCoV) strains 229E
(HCoV-229E), NL63 (HCoV-NL63), OC43 (HCoV-OC43), and
HKU1 (HCoV-HKU1) cause a signiﬁcant portion of upper
and lower respiratory tract infections in humans, including
common colds, bronchiolitis, and pneumonia. They have also
been implicated in otitis media, exacerbations of asthma,
diarrhea, myocarditis, and neurological disease [2,3,6–9]. A
previously unknown HCoV, severe acute respiratory syn-
drome coronavirus (SARS-CoV), which is most closely related
to the group II CoVs [10], proved to be the etiological agent
of a global outbreak of a life-threatening form of pneumonia
called severe acute respiratory syndrome (SARS), which, in
2003, was the cause of more than 800 fatalities worldwide [11–
14]. Animal CoVs are mainly associated with enteric and
respiratory diseases in livestock and domestic animals. Most
of the viruses are highly contagious with signiﬁcant mortality
in young animals, resulting in considerable economic losses
worldwide [5,9].
Although vaccines have been developed against avian
infectious bronchitis virus (IBV), canine CoV, and porcine
transmissible gastroenteritis virus (TGEV) to help prevent
serious diseases, several potential problems remain. Vacci-
nation against IBV is only partially successful due to the
continual emergence of new serotypes and recombination
events between ﬁeld and vaccine strains. The development of
vaccines against feline infectious peritonitis virus (FIPV) has
been frustrated by the phenomenon of antibody-dependent
enhancement. No licensed vaccines or speciﬁc drugs are
available to prevent HCoV infection [6,9]. Following the
SARS outbreak, a series of inhibitors was reported against the
helicase and main protease (M
pro) of SARS-CoV to prevent
viral replication [15–20]. However, previous research has only
placed emphasis on SARS-CoV, and no structural data are
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In common with other RNA viruses employing RNA-
dependent RNA polymerases for genome replication, CoVs
are generally thought to mutate at a high frequency [21],
although this phenomenon remains to be studied in detail.
During the SARS epidemic in China, the emergence of SARS-
CoV suggested an animal–human interspecies transmission
[22,23]. The virus continued evolving to adapt to the human
host during the course of the outbreak [22] with about one-
third the mutation rate of human immunodeﬁciency virus
[24]. The high degree of similarity between genome sequences
of bovine CoV and the recently sequenced HCoV-OC43
suggested an earlier animal-to-human interspecies trans-
mission than SARS-CoV [25]. Moreover, a high frequency of
RNA recombination is a common feature of CoV genetics
and has been demonstrated for representative viruses from
all CoV groups, including murine hepatitis virus (MHV),
TGEV, and IBV [9,26]. For instance, the outbreaks caused by
variant strains of IBV that arose from recombination of
vaccine and wild-type virulent strains in chicken ﬂocks limit
the usage of vaccines against IBV [27,28]. Consequently, it is
of concern whether current vaccines or drugs in development
will be effective against the next wave of attacks by altered
SARS-CoV [22].
In view of the issues posed above, the development of wide-
spectrum drugs against the existing pathogenic CoVs is a
more reasonable and attractive prospect than individual
strategies for drug design, and thereby could provide an
effective ﬁrst line of defense against future emerging CoV-
related diseases such as SARS. However, some of the key
factors controlling the host spectrum and viral pathogenicity
are highly variable among CoVs. For instance, CoVs use
different host receptors for cellular entry, have poorly
conserved structural proteins (antigens), and encode diverse
accessory genes in their 3’-terminal genome regions that
probably contribute to the pathogenicity of CoVs in speciﬁc
hosts [1–3,29–34]. Clearly, this structural and functional
diversity presents a signiﬁcant obstacle for designing a
versatile compound against all CoVs unless a highly con-
served target that is comparatively stable during evolution is
identiﬁed within the genus Coronavirus. Here we report the
discovery of a highly conserved region based on four crystal
structures and one homology model of M
pro representing all
three genetic clusters of the genus Coronavirus, and a uniform
inhibition mechanism revealed from the structures of M
pro-
inhibitor complexes from SARS-CoV and TGEV. A structure-
assisted optimization program has yielded compounds with
fast in vitro inactivation of multiple CoV M
pros, potent
antiviral activity, and extremely low cellular toxicity in cell-
based assays. Further modiﬁcation could rapidly lead to the
discovery of a single agent with clinical potential against
existing and possible future emerging CoV-associated dis-
eases.
Results/Discussion
Target Identification
Development of wide-spectrum inhibitors is an attractive
strategy against CoV-associated diseases; however, it entirely
depends on the availability of a conserved target within the
whole genus Coronavirus. During the ﬁrst round of target
screening, all structural proteins (including S, E, M, HE, and N
proteins) were excluded due to the considerable variations
among different CoVs [1–3,33,34]. Subsequently, the RNA-
dependent RNA polymerase, RNA helicase, and M
pro con-
stitute attractive potential nonstructural protein targets for
consideration. However, no structural data were available for
the former two proteins, increasing the difﬁculties for
rational drug design and downstream modiﬁcation of
possible drug leads.
The pivotal roles played by M
pros in controlling viral
replication and transcription through extensive processing of
replicase polyproteins, together with the absence of closely
related cellular homologues, identify the M
pro as a potentially
important target for antiviral drug design [35]. However,
pairwise BLAST of the primary sequences among CoV M
pros
showed identities of only 38% in some cases. Since it is
acknowledged that three-dimensional structures are more
closely conserved than primary sequences, we decided to
investigate the conservation among the CoV M
pro structures.
As the M
pros showed comparatively high sequence similarity
within each CoV group, representatives from every group
were chosen for comparison. The structures of M
pros from
TGEV (group I), HCoV-229E (group I), and SARS-CoV are
available [36–38]. Although the crystal structure of IBV
(group III) M
pro is currently under reﬁnement by our group,
it can nevertheless be used as an experiment-based model. As
the structure of MHV M
pro (group II) was unavailable, and
previous studies have shown that SARS-CoV is related to
group II [10], we constructed a homology model for MHV
M
pro based on the structure of SARS-CoV M
pro. Super-
position of the crystal structures and homology model
showed approximately 2 A ˚ root mean square deviation for
all 300 Ca, but the most variable regions were the helical
domain III and surface loops. The substrate-binding pockets
located in a cleft between domains I and II, and especially the
S4, S2, and S1 are highly conserved among CoV M
pros
suggesting the possibility for wide-spectrum inhibitor design
targeting this region in the M
pros of all CoVs. This hypothesis
was further supported by enzyme activity assays (see Table 1).
Based on the assumption that the substrate-binding sites are
highly conserved among CoV M
pros, a ﬂuorescence-labeled
substrate MCA-AVLQﬂSGFR-Lys(Dnp)-Lys-NH2 was synthe-
sized to determine the kinetic parameters of TGEV, HCoV-
229E, FIPV, MHV, IBV, and SARS-CoV M
pros. The substrate
sequence was derived from residues P4–P59 of the SARS-CoV
M
pro N-terminal autoprocessing site, which has the sequence
AVLQSGFRK. IBV M
pro demonstrated an almost identical Km
to that of SARS-CoV M
pro. An interesting observation was
that four other CoV proteases showed marginally stronger
binding afﬁnity to the substrate than SARS-CoV M
pro itself.
These results further support the preliminary biochemical
studies on conservation of substrates of CoV M
pros [39].
First Round of Inhibitor Design: Michael Acceptor
Inhibitors
The structures of TGEV and SARS-CoV M
prosh a v e
previously been determined in complex with a substrate-
analog chloromethyl ketone (CMK) inhibitor, Cbz-VNSTLQ-
CMK. The sequence of this substrate-analog was derived from
residues P6–P1 of the N-terminal autoprocessing site of
TGEV M
pro [36,38]. However, the two protomers of SARS-
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prosCoV M
pro each exhibited an unexpected binding mode,
possibly resulting from the comparatively weak binding of
peptidyl elements derived from the substrate of TGEV M
pro
and from the highly reactive electrophile CMK. This would
suggest that nucleophilic attack might have occurred before
a stable noncovalently bound enzyme-inhibitor complex was
formed. Accordingly, the single binding mode in the TGEV
M
pro complex was taken into account when designing
possible broad-spectrum inhibitors on the basis of these
structures and models. Although the CMK inhibitor is
nonselective because of its high chemical reactivity and is
susceptible to cleavage by gastric and enteric proteinases, it
could provide structural insight into the substrate-binding
pocket. Superposition of the structures and model revealed
that all these proteases have a His–Cys catalytic dyad with
relatively conserved orientations, in which His acts as a
proton acceptor and Cys undergoes nucleophilic attack on
the carbonyl carbon of the substrate. It is widely accepted
that increased inhibitor potency can be achieved provided
that a covalent bond is formed between the active Cys
residue and the designed compound, resembling the
intermediate during substrate cleavage. The Michael accept-
ors, a class of conjugated carbonyl compounds, were
successfully introduced to devise irreversible Cys protease
inhibitors, including the antirhinovirus compound ruprin-
trivir (formerly designated AG7088) [40–42], and so the
highly reactive electrophile CMK was replaced by a less
reactive trans-a, b-unsaturated ethyl ester, which was
expected to readily extend into the bulky S19 subsite of
CoV M
pros.
During our initial round of inhibitor design, we focused
on the S1, S2, and S4 subsites crucial for substrate
recognition and utilized a strategy for mimicking the
substrate side chains of residues P4–P1 to accommodate
the corresponding subsites. Since backbones of CoV M
pros
constituting this area superimposed particularly well, except
for a small segment located on the outer wall of S2, we
concentrated on the variation of side chains forming these
pockets. In the TGEV M
pro complex structure [36], the side
chains of 165-Glu, 162-His, 171-His, and 139-Phe (also
conserved in other M
pros) are incorporated with other
backbone elements to constitute the S1 site, which has an
absolute requirement for Gln at the P1 position via two
hydrogen bonds. Modeling showed that a lactam with (S)
stereochemistry at the a-carbon might preserve the hydro-
gen bonds essential for S1 recognition; moreover, a
comparatively bulky lactam ring would create additional
van der Waals interactions. The side chains of 164-Leu, 51-
Ile, 41-His, and 53-Tyr, as well as the alkyl portion of side
chains of 186-Asp and 47-Thr, are involved in forming a
deep hydrophobic S2 subsite that can accommodate the
relatively large side chain of Leu in TGEV M
pro. This feature
can also be observed in the HCoV-229E M
pro. Several
conservative substitutions occur in other CoV M
pros (164-
Leu ! 165-Met in SARS-CoV and MHV M
pros; 53-Tyr ! 50-
Trp in IBV M
pro). Another minor difference was observed in
SARS-CoV and MHV M
pros, where the outer wall segment is
composed of a short 310-helix from residues 45–50,
compared with a less regular structure in HCoV and TGEV
M
pro. With respect to the structure of IBV M
pro undergoing
reﬁnement, no clear electron density was observed in the
corresponding stretch of residues 44–47. We reasoned that
variations in the segment located on the outer wall of S2
should not signiﬁcantly affect the hydrophobicity of this
deep subsite. This is supported by evidence wherein Leu is
found at position P2 of substrates for all CoV M
pros. As P2
Table 1. Enzyme Activity and Enzyme-Inhibition Data for Representatives of All Genetic Clusters of Genus Coronavirus
Anti-
genic
Group
Virus
M
pro
Km
(lM)
Kcat
(s
 1)
N1 N9 N3
Ki (lM) k3
(3 10
 3s
–1)
kobs/[I]
(M
 1 s
 1)
Ki
(lM)
k3
(3 10
 3s
–1)
kobs/[I]
(M
 1 s
 1)
Ki
(lM)
k3
(3 10
 3s
–1)
kobs/[I]
(M
 1 s
 1)
IH C o V -
229E
29.8 6 0.9 1.27 6 0.09 1.11 6 0.09 14.8 6 0.7 — 0.9 6 0.1 12.1 6 0.7 — 1.67 6 0.18 18.0 6 1.1 —
TGEV 61 6 51 . 3 9 6 0.09 3.2 6 0.2 50 6 3— 7 . 8 6 0.7 19.5 6 0.9 — — — 13,000
FIPV 13.5 6 1.8 0.60 6 0.06 — — 24,000 — — 23,000 — — 47,000
II MHV 77 6 50 . 0 8 3 6 0.006 — — 2,800 — — 660 — — 4,800
SARS-
CoV
a
129 6 70 . 1 4 6 0.01 10.7 6 1.0 4.1 6 0.7 — 6.7 6 0.4 2.6 6 0.2 — 9.0 6 0.8 3.1 6 0.5 —
III IBV 139 6 15 0.22 6 0.03 3.9 6 0.9 14.5 6 1.2 — 4.9 6 0.4 5.6 6 0.1 — — — 7,900
aSARS-CoV is related to the group II CoVs.
DOI: 10.1371/journal.pbio.0030324.t001
Figure 1. Structures of Inhibitors and Their Interactions with SARS-CoV M
pro
(A) The structures of compounds I2, N1, and N3.
(B) A stereo view showing I2 bound into the substrate-binding pocket of the SARS-CoV M
pro at 2.7 A ˚. The I2 inhibitor is shown in gold and covered by
an omit map contoured at 1.0 r. Residues forming the substrate-binding pocket are shown in silver.
(C) A stereo view showing N1 bound into the substrate-binding pocket of the SARS-CoV M
pro at 2.0 A ˚. The N1 inhibitor is shown in gold and covered by
an omit map contoured at 1.0 r. Residues forming the substrate-binding pocket are shown in silver. Two water molecules (in red) form hydrogen bonds
with N1.
(D) Detailed view of the interactions between the N1 and SARS-CoV M
pro. The N1 inhibitor is shown in green. Hydrogen bonds are shown as dashed
lines, and interaction distances are given. The covalent bond is labeled in red.
DOI: 10.1371/journal.pbio.0030324.g001
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prosPhe is present in the C-terminal autocleavage site of SARS-
CoV, phenyl was used as a smaller substituent to explore this
subsite. The side chain of Thr at P3 is solvent-exposed, so
this site was expected to tolerate a wide range of
functionality. The side chains of 164-Leu, 166-Leu, 184-
Tyr, and 191-Gln that form the S4 hydrophobic subsite of
TGEV are conserved in other CoV M
pros, excluding the
following conservative substitutions: 184-Tyr ! 184-Phe in
HCoV M
pro; 164-Leu ! 165-Met, 184-Tyr ! 185-Phe in
SARS-CoV. A tertiary butyloxycarbonyl was introduced at
the P4 position as an N-terminal protecting group to enter
into the S4 site. Thus, by combining the modiﬁcations above,
a novel compound designated as I2 (see Figure 1A) was
designed and a series of analogs was synthesized for the
inhibition assay (see Protocol S1).
Kinetic Mechanism of Michael Acceptor Inhibitors
Covalent irreversible inactivation of CoV M
pros by Michael
acceptor inhibitors proceeds according to the kinetic
mechanism presented in the scheme below:
E þ I_
k1
k2
EI]
k3 E   I ð1Þ
The inhibitor initially forms a reversible complex with the
protease, which then undergoes a chemical step (nucleophilic
attack by Cys) leading to the formation of a stable covalent
bond [42]. The evaluation of this series of time-dependent
inhibitors requires both the equilibrium-binding constant Ki
(designated as k2/k1) and the inactivation rate constant for
covalent bond formation k3 [43]. We avoided measurement of
IC50 after preincubation to assess the effect of these time-
dependent inhibitors, since there is a general trend for this
value to decrease to zero with prolonged preincubation time,
which would lead to an inappropriate evaluation.
The Structure of SARS-CoV M
pro in Complex with an
Inhibitor I2
The compounds designed in the ﬁrst round did not exhibit
obvious inhibition on CoV M
pros without preincubation,
suggesting a very poor Ki. We were able to solve a 2.7-A ˚
resolutioncrystalstructureofSARS-CoVM
procomplexedwith
I2 (see Figure 1B; Table S1) despite the weak noncovalent
binding, in order to enhance the inhibitory effect of these
compounds. Brieﬂy, compound I2 binds to the shallow cleft
formedbyaportionofthestrandeIIandasegmentoftheloop
linkingdomainsIIandIII.TheCbatomoftheMichaelacceptor
forms a covalent bond with Sc of 145-Cys as expected. The
lactam P1 inserts favorably into S1 and the side chain of Val at
P3 is solvent-exposed. However, the failure of P2 and P4 to be
properly accommodated by their corresponding subsites
attracted our attention, and might account for the poor
inhibitory effect of this series of molecules. First, although
phenylatP2couldentertheS2site,itsrigiditypreventsitfrom
reorienting to insert further into this site. Second, the N-
terminal protecting group tertiary butyloxycarbonyl did not
insert into the S4 subsite, possibly as a result of the planar
property of the butyloxyamide group. The other compounds
designed in this round are listed in Table S2.
Second Round of Inhibitor Design: Optimization of
Michael Acceptor Inhibitors
Based on the complex structure of I2, we entered into a
second round of optimization focusing on the P2 and P4
recognition sites. For the P2 subsite, the phenyl group was
substituted by a more ﬂexible Leu side chain. In order to
enhance the binding afﬁnity, a series of residues were utilized
as substituents at P4, followed by a heterocycle that should
increase the Van der Waals contacts with residues ﬂanking at
either side. From this round of modiﬁcation, two inhibitors
designated as N1 and N9, and a more efﬁcacious derivative
named N3, were identiﬁed with fast in vitro inactivation of all
CoV M
pros tested, including those of TGEV, HCoV-229E,
FIPV, HCoV-NL63 (representatives from group I); MHV,
HCoV-HKU1 (representatives from group II); SARS-CoV
(related to group II); and IBV (representative from group III)
in preliminary inhibition assays (see Figure S2). These
inhibitors are not sensitive under 1 mM concentration of
dithiothreitol (DTT), which is consistent with a previous
report of this type of compound [42]. Subsequently, strict
inhibition kinetic parameters were determined and are listed
in Table 1 (determination of kinetic parameters of M
proso f
HCoV-HKU1 and HCoV-NL63 is underway). These inhibitors
showed more powerful inhibition of FIPV M
pro than other
proteases with high inactivation rates (kobs/[I]   23,000
M
 1 s
 1), such that measurement of Ki and k3 proved difﬁcult.
In this case, kobs/[I] was utilized to evaluate their inhibition as
an approximation of the pseudo second-order rate constant
(k3/Ki) if very rapid inactivation occurs. The Ki of N1 ranges
from approximately 1.11–10.7 lMa n dk3 ranges from
approximately 4.1–50 3 10
 3s
 1; the Ki of N9 ranges from
approximately 0.9–6.7 lM, and k3 ranges from approximately
2.6–19.5 3 10
 3s
 1. Compared with N1 and N9, N3 demon-
strated more potent inhibition on TGEV, FIPV, MHV, and
IBV M
pros with kobs/[I] ranging from approximately 4,700–
47,000 M
 1 s
 1. We therefore solved the crystal structure of
SARS-CoV and TGEV M
pros individually complexed with N1,
which revealed a common mechanism of inhibition among
CoV M
pros.
The Structure of SARS-CoV M
pro in Complex with the
Inhibitor N1
N1 binds to protomers A and B of SARS-CoV in an
identical and normal manner. On binding N1, the S1 subsite
in protomer B adopts an active conformation compared with
the partially collapsed S1 pocket of protomer B in the native
structure [38], which can be ascribed to inhibitor-induced
conformational changes. As a result, discussion will be
focused entirely on protomer A (see Figures 1C, 1D, 2A,
and 2B). From the omit map (contoured at 1.2 r), clear
electron density showed that N1 binds in an extended
conformation with the inhibitor backbone atoms forming
an antiparallel sheet with residues 164–168 of the long strand
eII on one side, and with residues 189–191 of the loop linking
domains II and III. Here we dissect the inhibitor into
different parts for further discussion.
Gate-regulated switch. Comparison between the molecular
surfaces of SARS-CoV M
pro complexed with N1 and the
native enzyme show that certain residues constituting the S1
and S2 subsites undergo large conformational changes on
inhibitor binding (see Figure 2A and 2B). The side chain of
142-Asn ﬂips over with a 6-A ˚ shift to superpose onto the
lactam like a lid when P1 inserts into the subsite. This might
account for the movement of main chains of residues 141–
143 toward the S1 site; 142-Asn, together with the main
chains of neighboring residues, covers the P1 site like one half
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prosof a gate. On the opposite side, 49-Met protrudes by around
5A ˚ from the hydrophobic S2 site and is situated parallel to
the side chain of Leu at P2. The side chain of another residue,
189-Gln, moves upward to form a 3.0-A ˚ hydrogen bond with
the backbone NH of P2. These two residues constitute the
other half of a gate. Together, these two halves should serve as
a gate-regulated switch with an essential role in substrate or
inhibitor recognition and binding.
Trans-a, b-unsaturated ethyl ester. Clear electron density
showed that the Sc atom of 145-Cys forms a standard 1.8-A ˚ C–
S covalent bond with the Cb of vinyl group, which suggests a
Michael addition reaction. The Sc atom moved slightly
(approximately 0.6 A ˚ ) toward the interior of the protein
compared with the native enzyme. The Michael acceptor
remains in a plane following the Michael addition since it is
stabilized by a water molecule. This ordered water molecule
donates a long 3.3-A ˚ hydrogen bond to the carboxylate
oxygen of the ester and then accepts a 2.8-A ˚ hydrogen bond
from the backbone NH of 143-Gly and a 3.0-A ˚ hydrogen bond
from the carboxamide nitrogen of 142-Asn. The position of
Sc in 145-Cys implies that it undergoes nucleophilic attack on
Cb by approaching the p-electron cloud from above. The
carbonyl oxygen occupies the oxyanion hole and is close to
backbone NHs of 143-Cys and 145-Cys, mimicking the
tetrahedral oxyanion intermediate formed during Ser pro-
tease cleavage. However, the standard hydrogen bonds are
not formed. The ethyl ester portion extends into the S19 site,
with sufﬁcient size, and in an extended conformation, to
interact with the alkyl portions of 25-Thr and 27-Leu by van
der Waals interaction.
P1, P2, and P4 sites. The lactam at P1 inserts favorably into
the S1 subsite and forms two stable 2.6-A ˚ hydrogen bonds:
one between the lactam oxygen and NE2 of 163-His, and
another between the lactam NH and a water molecule at the
bottom of this subsite. The Ca of Leu at the P2 site in N1
moves into the S2 subsite by approximately 1 A ˚ relative to the
corresponding carbon atom in I2, and Cb–Cc of Leu forms an
angle of approximately 408 to the phenyl at P2 in the I2
complex, inserting deeply into the S2 subsite. Another
notable difference between N1 and I2 is the insertion of an
Ala between P3 and P4 in I2, the latter of which was replaced
by an isoxazole to block the N-terminal. As expected, the side
chain of Ala at the current P4 position readily enters into the
S4 subsite. Simultaneously, the backbone NH of Ala donates a
hydrogen bond to the carbonyl oxygen of 190-Thr. The
isoxazole at P5 makes Van der Waals contacts with 168-Pro
and the backbone of residues 190–191.
Further modiﬁcations of N1. A variety of substitutions were
investigated for P4, P5, and P19 (see Table S3). The 1.85-A ˚
crystal structure of SARS-CoV M
pro complexed with N9 (see
Figure S1) showed that Val could serve as a substituent at P4,
slightly increasing the hydrophobic interactions. Another
derivative N3 with benzyl ester exhibited improved inhib-
ition, which could be seen from inhibition assays of FIPV and
MHV M
pros (see Table 1). Its co-crystal structure with SARS-
CoV M
pro indicated that the bulky benzyl group extends into
Figure 2. Surface Representation of Native SARS-CoV M
pro and Inhibitor
Complexes
(A) Surface representation of conserved substrate-binding pockets of five
CoV M
pros. Background is SARS-CoV M
pro. Red: identical residues among
the five CoV M
pros; magenta: substitution in one CoV M
pro; orange:
substitution in two CoV M
pros. The S1, S2, S4, and S19 subsites and
residues forming the substrate-binding pocket are labeled.
(B) Surface representation of SARS-CoV M
pro (blue) complexed with N1
(green). Water molecules are shown as red spheres. The P1–P5 and P19
groups and residues forming the substrate-binding pocket are labeled.
(C) Surface representation of SARS-CoV M
pro (blue) in complex with N3
(green). Labels are the same as in Figure 2B.
DOI: 10.1371/journal.pbio.0030324.g002
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prosthe S19 site, possibly enhancing the Van der Waals interaction
with 25-Thr and 27-Leu (see Figure 2C).
The Structure of TGEV M
pro in Complex with an Inhibitor
N1
There are two molecules per asymmetric unit in the co-
crystal structure of TGEV M
pro with N1, compared with as
many as six molecules per asymmetric unit in the native
enzyme structure [37]. N1 binds to TGEV M
pro in a similar
mode to SARS-CoV M
pro with some subtle differences (see
Figure 3). First, after the nucleophilic addition reaction, the
Michael acceptor does not remain in a plane as in the SARS-
CoV M
pro complex structure, but instead ﬂips over by about
908 to interact with the backbone atoms of residues 141–142.
Unlike the SARS-CoV M
pro complexed with N1, the TGEV
M
pro lacks a water molecule connecting the ethyl ester with
the side chain of residue 142 (Asn ! Ala in TGEV M
pro). The
rate of chemical inactivation presumably depends on how the
reactive vinyl group is oriented and on the extent to which
the transition-state intermediate can be stabilized by pro-
teases [42]. We suspect that in SARS-CoV M
pro, the water
molecule prevents the Michael acceptor from reorienting to
accept a proton from the imidazole of 41-His in the transition
state. Although the intermediate remains to be unveiled, this
could partially explain why N1 has a higher inactivation rate
constant (k3) against TGEV M
pro than SARS-CoV M
pros.
Second, another water molecule in the TGEV M
pro complex
occupies an equivalent position to the 189-Gln side chain,
which interacts with the backbone NH of Leu at P2 in SARS-
CoV M
pro–N1 complex. This water molecule, however,
donates a 2.6-A ˚ hydrogen bond to 47-Thr and accepts a 2.7-
A ˚ hydrogen bond from the NH backbone of Leu at P2. Third,
the isoxazole sways to interact with the backbone atoms of
residues 188–189. It is worth mentioning that these slight
variations do not notably affect the Ki, as the binding modes
of P1, P2, and P4 remain the same as in SARS-CoV M
pro.
HCoV-229E, FIPV, and MHV Inhibition Assays
Despite the high multiplicity and single-cycle infection
conditions, N3 displayed potent inhibition against HCoV-
229E, FIPV, and MHV-A59 with individual IC50 of 4.0 lM, 8.8
lM, and 2.7 lM, respectively (see Figure 4A–4C). The dose
response curves all show that N3 was able to penetrate cells
derived from different species and tissues to access its targets.
Consequently, the results strongly imply that N3 was a wide-
spectrum anti-CoV lead compound. However, we noticed
some small discrepancies in the data between enzyme-
inhibition assays and cell-based assays. This can be explained
by the different cells for the inhibitor to enter and by
potential incongruities in the dependence of M
pro for
different CoVs. Furthermore, we cannot exclude the poten-
tial existence of differences among the bacterially expressed
proteases in enzyme-inhibition assays and subtle differences
in activity that were not fully revealed by the SARS-CoV-
derived substrate used in our in vitro assays.
MHV Plaque-Reduction Assay
To further substantiate the data and, in particular, to
evaluate the ability of this type of compound to prevent cells
from being infected by CoVs and their cellular cytotoxicity, a
murine delay brain tumor (DBT) cell-based MHV plaque-
reduction assay was performed for the following reasons: (1)
three important human pathogens HCoV-HKU1, HCoV-
OC43, and SARS-CoV belong to or relate to group II CoVs;
(2) aged mice have been successfully used as a model for
increased severity of SARS in elderly humans [44]. The EC50
of the MHV plaque-reduction assay was 3.4 lM (see Figure
4D), which was consistent with the IC50 determined in the
MHV inhibition assay. It was observed that when the
concentration of N3 increased to 8 lM, the DBT cells could
be sufﬁciently protected. Moreover, 500 lMN 3o n l y
displayed 28.3% inhibition of cell growth, suggesting ex-
tremely low cellular toxicity (see Figure S3). These results
demonstrate that N3 is a particularly promising lead
compound for further development.
Future Prospects
Evidence suggests that CoVs may have completed at least
two animal-to-human interspecies transmissions to date
[22,24,25]. An alternative hypothesis has been proposed
whereby the 1889–1890 pandemic characterized by malaise,
fever, pronounced central nervous system symptoms, with a
Figure 3. The Structure of TGEV M
pro in Complex with N1
A stereo view showing N1 bound into the substrate-binding pocket of the TGEV M
pro at 2.7 A ˚. The N1 inhibitor is shown in gold and covered by an omit
map contoured at 1.0 r. Residues forming the substrate-binding pocket are shown in silver. The red sphere represents a water molecule that is
hydrogen bonded to N1.
DOI: 10.1371/journal.pbio.0030324.g003
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prossigniﬁcant increase in case fatality with increasing age, was
the result of interspecies transmission of bovine CoV to
humans rather than an inﬂuenza virus [25]. Although this
hypothesis needs more evidence to support, it is widely
acknowledged that SARS resulted from animal-to-human
transmission of a previously unknown CoV. CoVs, especially
those that can infect hosts such as domestic animals and pets,
which humans have frequent contact with, remain a potential
threat to human health assuming they cross the interspecies
barrier again. Hence, the development of wide-spectrum
drugs will lead to increased protection of human health, a
reduction of the considerable economic costs associated with
CoVs, defense against endangered wild animals susceptible to
infection, and valuable model animals such as transgenic mice
with high mortality rates for CoVs. Identiﬁcation of the CoV
M
pro as a conserved target among all CoVs will provide an
opportunity for the development of broad-spectrum inhib-
itors against all CoV-related diseases. Ruprintrivir, whose
backbone was also a trans-a, b-unsaturated ester incorporated
with the peptidyl portion, has entered clinical trials against
rhinovirus infection [42], although it did not show inhibition
of CoVs [20]. This is a compound with poor aqueous solubility
and low oral bioavailability in animals. In preclinical animal
studies, hydrolysis of this compound produced alcohol and
carboxylic acid metabolite, which was 400-fold less active
than ruprintrivir and was the predominant biotransforma-
tion pathway. Ruprintrivir is formulated as a suspension for
intranasal delivery. Phase II studies reported ruprintrivir
prophylaxis reduced the proportion of subjects with positive
viral cultures and viral titers. Ruprintrivir is well tolerated,
and the most common adverse effects of this compound are
blood-tinged mucus and nasal passage irritation [45,46]. This
highlights that structure-assisted optimization of N3 could
possibly lead to the discovery of a single agent to enter
clinical trials against all CoV-associated diseases, although
ultimate clinical potential requires more sufﬁcient inves-
tigation. Our latest results show that N3 could also strongly
inhibit the replication of SARS-CoV and TGEV in cell-based
assays (data to be published elsewhere). Furthermore, since
this compound was designed against a highly conserved
region within the genus Coronavirus, it should have efﬁcient
resistance to the high mutation and recombination rates of
CoVs. It is noteworthy that N3 also exhibited potent
inhibition on the M
pros of HCoV-NL63 and HCoV-HKU1,
two recently identiﬁed HCoVs associated with bronchiolitis,
conjunctivitis, and pneumonia [2,3], in preliminary inhibition
assays (see Table S2). This strongly supports our hypothesis
that a single agent developed from N3 could provide an
effective ﬁrst line of defense against future emerging CoV-
related diseases. Moreover, it also suggests that incorporation
of Michael acceptor with the peptidyl portion speciﬁc for
proteases would be a good starting point for the development
of inhibitors against viral Cys or Ser proteases. A compre-
hensive and systematic program of optimization of this class
of inhibitors based on CoV M
pro-inhibitor complexes is
underway. We have so far crystallized MHV M
pro, and the
crystallization of M
pros of recently identiﬁed HCoV-NL63 and
HCoV-HKU1 are in progress.
Materials and Methods
Protein cloning, expression, and puriﬁcation. The preparation of
SARS-CoV M
pro for structural analysis has been described previously
[38]. The method of preparation of SARS-CoV M
pro for activity assay
is almost identical except that the coding sequence was inserted into
BamHI and XhoI sites of the expression vector pGEX-4T-1
(Pharmacia, New York, United States). The cDNA encoding IBV M
pro
(M41 strain) was a gift from Professor Ming Liao (South China
Agricultural University, China); the cDNA encoding M
pro of MHV
(A59 strain) was a gift from Professor Guangxia Gao (Institute of
Biophysics Chinese Academy of Sciences, China); the cDNA encoding
M
pro of HCoV-HKU1 was kindly provided by Professor Kwok-yung
Yuen (University of Hong Kong, China); coding sequences of TGEV,
IBV, HCoV-HKU1, and HCoV-NL63 M
pros were inserted into BamHI
and XhoI sites of the pGEX-4T-1 plasmid, and the subsequent
methods for expression and puriﬁcation were carried out as for
SARS-CoV M
pro. After change of a BamHI cleavage site at 429–434 in
the sequence coding MHV M
pro to GGCTCC, this coding sequence
was inserted into BamHI and XhoI sites of pGEX-4T-1 plasmid for
expression. FIPV M
pro (15 mg/ml) and HCoV-229E M
pro (15 mg/ml;
two amino acids deleted at C-terminal) were expressed and puriﬁed
as described previously [39,47].
Crystallization and data collection. SARS-CoV M
pro was crystallized
as previously reported [38]. The SARS-CoV M
pro inhibitor complexes
were prepared as follows. First, the inhibitors were dissolved in 7.5%
PEG 6000, 6% DMSO, and 0.1 M Mes (pH 6.0) with a concentration of
10 mM (supersaturation). Then, a 3-ll aliquot of such solution was
added to the drop, and the crystals were soaked for approximately 2–
6 days. A single crystal was prepared for low-temperature data
collection by transfer to a cryoprotectant solution containing 30%
PEG 400 and 0.1 M Mes (pH 6.0) and then ﬂash frozen in a stream of
N2 gas at 100 K. The set of SARS-CoV M
pro-I2 complex data was
collected to 2.7 A ˚ resolution using a Mar345 image plate (Marre-
search, Norderstedt, Germany) mounted on a Rigaku RU2000 X-ray
generator (Sevenoaks, United Kingdom) operated at 48 kV and 98 mA
(k¼1.5418 A ˚ ). Data for SARS-CoV M
pro individually complexed with
N1 and N3 were collected at 100 K in-house on a Rigaku CuKa
rotating-anode X-ray generator (MM007) at 40 kV and 20 mA (k ¼
1.5418 A ˚ ) with a Rigaku image-plate detector. Data for SARS-CoV
M
pro-N9 complex were collected at 100 K in-house on a Rigaku CuKa
rotating-anode X-ray generator (FR-E) at 45 kV and 45 mA (k ¼
1.5418 A ˚ ) with a Rigaku image-plate detector.
In respect to TGEV M
pro co-crystal preparation, TGEV M
pro was
Figure 4. Cell-Based Assays of N3 against HCoV-229E, FIPV, and MHV-
A59
Inhibition of replication of three CoVs under high-multiplicity single-
cycle growth conditions (MOI¼3) and protection of DBT cells from MHV
infection under low-multiplicity growth conditions (MOI ¼ 0.01). (A)
Reduction of HCoV-229E titer in MRC-5 cell culture by N3. (B) Reduction
of FIPV titer in FCWF cell culture by N3. (C) Reduction of MHV-A59 titer in
DBT cell culture by N3. In (A–C), infections were done at an MOI of 3
TCID50 per cell, and titers were determined at 14 h postinfection. (D)
Plaque-reduction assay of MHV-A59.
FCWF, F. catus whole fetus; MOI, multiplicity of infection.
DOI: 10.1371/journal.pbio.0030324.g004
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prosincubated with a 3-fold molar excess of N1 for 24 h at 4 8C.
Crystallization trials were performed by the method published
previously [37]. Brieﬂy, the condition for crystal growth is 0.1 M
HEPES (pH 8.5), 1.8 M (NH4)2SO4, 6% MPD, 5 mM DTT, and 5%
dioxane. The set of TGEV M
pro-N1 complex data was collected
according to the method for SARS-CoV M
pro-N9 complex All
intensity data were indexed, integrated, and scaled with the
HKL2000 programs DENZO and SCALEPACK [48]. Data collection
statistics are summarized in Table S1. Since the reﬁnement of the IBV
M
pro structure is ongoing, the methods of crystallization and
structure determination will be published elsewhere.
Structure elucidation, model building, and reﬁnement. The
methods for structure determination, model building, and reﬁnement
werepublishedpreviously[38].Brieﬂy,theSARS-CoVM
pro-I2complex
structure was determined by molecular replacement from our native
structure of SARS-CoV M
pro (pH 7.6) (PDB ID: 1UK3). The structures
of SARS-CoV M
pro in complex with N1, N3, or N9 were determined
from the isomorphous SARS-CoV M
pro-I2 complex structure. The
TGEV M
pro-N1 structure was determined by molecular replacement
using a single monomer of the native TGEV M
pro structure (PDB ID:
1P9U). All cross-rotation and translation searches for molecular
replacement were performed with CNS [49]. Adjustments to the
modelsweremadeinO[50].Positionalreﬁnement,individualB-factor
reﬁnement, and water picking were performed with CNS [49].
Validation of the ﬁnal models was performed with PROCHECK [51].
Detailed reﬁnement statistics are summarized in Table S1.
Enzyme activity assay. The activity of M
pros was measured by
continuous kinetic assays, using an identical ﬂuorogenic substrate
MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 (over 95% purity, GL Biochem
Shanghai Ltd, Shanghai, China). The ﬂuorescence intensity was
monitored with a Fluoroskan Ascent instrument (ThermoLabsystems,
Helsinki, Finland) using wavelengths of 320 and 405 nm for excitation
and emission, respectively. The experiments were performed with a
buffer consisting of 50 mM Tris-HCl (pH 7.3), 1 mM EDTA, with or
without DTT. Kinetic parameters, Km and kcat, were determined by
initial rate measurements at 30 8C. With respect to SARS-CoV M
pro,
the reaction was initiated by adding protease (ﬁnal concentration of 1
lM) to a solution containing different ﬁnal concentrations of the
substrate (3.2–40 lM). The concentrations of other M
prosa n d
individual substrate range for activity assay are as follows: IBV M
pro:
0.8 lM, substrate range: 6.4–80 lM; HCoV-229E M
pro: 0.1 lM,
substrate range: 1.6–20 lM; TGEV M
pro: 0.1 lM, substrate range: 6.4–
80 lM; FIPV M
pro: 0.1 lM, substrate range: 1.6–20 lM; MHV M
pro:1
lM, substrate range: 6.4–80 lM. Fluorescence was monitored at 1
point per 2 s. Initial rates were calculated by ﬁtting the linear portion
of the curves (the ﬁrst 3 min of the progress curves) to a straight line
using the program Origin 7.0 (OriginLab Corporation, Natick,
Massachusetts, United States). The initial velocities were converted
to enzyme activity (micromole substrate cleaved)/second. Kinetic
constants were obtained from a double-reciprocal plot.
M
pro inhibition assays. As compounds with potent inhibition
identiﬁed in preliminary inhibition assay, the strict kinetic param-
eters were determined. Time-dependent inhibitor progress curves
were ﬁt to a ﬁrst-order exponential (equation 2) [43,52] to yield an
observed ﬁrst-order inhibition rate constant (kobs). P is the product
ﬂuorescence; v0 is the initial velocity; t is time; D is a displacement
term to account for the fact that the emission is nonzero at the start
of data collection. The values of Ki and k3 were calculated from plots
of 1/kobs obtained from equation 2 versus 1/[I] according to equation 3.
[I] is inhibitor concentration; [S] is substrate concentration; Km is the
Michaelis-Menten constant for the substrate; k3 is the rate constant of
inactivation, and Ki is the equilibrium constant.
P ¼ð v0=kobsÞð1   expð kobstÞÞ þ D ð2Þ
1
kobs
¼
1
k3
þ
Ki
k3
ð1 þ½ S =KmÞ 
1
½I 
ð3Þ
In the experiment, the Ki and k3 values for the irreversible inhibitors
were obtained from reactions initiated by addition of individual M
pro,
the concentration of which was similar as that for the enzymatic
activity assay, containing 10 or 20 lM substrate, which depends on the
enzymatic activity. The inhibitors vary from 5–8 different concen-
trations (10-fold molar excess of the enzyme in most cases). Data from
the continuous assays were analyzed with the nonlinear regression
analysis program Origin. When fast inactivation occurs, the measure-
ment of Ki and k3 proved difﬁcult. In this case, kobs/[I] was used as an
approximation of the pseudo second-order rate constant to evaluate
the inhibitors and was measured at approximately 2–4 different
inhibitor concentrations. The error associated with this determina-
tion (kobs/[I]) is less than 20% of a given value.
MHV-A59 plaque-reduction assay. Murine DBT cells (generously
provided by Dr. Lishan Su of University of North Carolina) were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum (FBS) and antibiotics at 37 8Ci n5 %C O 2.
DBT cells were suspended in growth medium in triplicate wells in
6-well plates and preincubated with appropriate concentrations of
the inhibitor. The next day, the medium was aspirated, and MHV-A59
was added to each well at a titer of 100 PFU/well. After incubation for
1 h, the virus inoculum was aspirated, and 2 ml of a media-agar
overlay with appropriate concentrations of inhibitor was added to
each well. The plates were further incubated for 24 h and stained with
neutral red to visualize plaques.
Cytotoxicity assay. DBT cells were suspended in growth medium in
96-well plates. The next day, appropriate concentrations of the
inhibitor were added to the medium. Two days later, the relative
numbers of surviving cells were measured by MTT (Sigma, St. Louis,
Missouri, United States) assay in accordance with the manufacturer’s
instructions.
HCoV-229E, FIPV, and MHV-A59 infection assays. Human
embryonic lung ﬁbroblast cells (MRC-5; ATCC [Manassas, Virginia,
United States]: CCL 171), Felis catus whole fetus (macrophage) cells
(FCWF, ATCC: CRL 2787), and DBT cells were cultured in minimal
essential medium (MEM) supplemented with 25 mM HEPES,
Glutamax I, nonessential amino acids, 10% FBS, and antibiotics at
37 8Ci n5 %C O 2. Nearly conﬂuent monolayers of MRC-5 (incubated
at 33 8C following infection), FCWF, and DBT cells, which were grown
in 6-well plates, were infected with HCoV-229E, FIPV (strain 79–
1146), and MHV-A59, respectively, at a multiplicity of infection of 3
TCID50 per cell. After 60 min of virus adsorption, the virus inoculum
was replaced with cell culture medium containing varying concen-
trations of N3 or in the absence of inhibitor. At 14 h postinfection,
the virus titers in the cell culture supernatants were determined using
standard procedures. All experiments were performed in triplicate
and mean values were determined.
Supporting Information
Figure S1. A Stereo View Showing N9 Bound into the Substrate-
Binding Pocket of the SARS-CoV M
pro at 1.85 A ˚
The N9 inhibitor is shown in gold and covered by an omit map
contoured at 1.0 r. Residues forming the substrate-binding pocket
are shown in silver. Two water molecules (in red) form hydrogen
bonds with N9.
Found at DOI: 10.1371/journal.pbio.0030324.sg001 (425 KB PDF).
Figure S2. N3 Has Wide-Spectrum Inhibition on CoV M
pros
Activity proﬁle curves were displayed at two different inhibitor
concentrations for (A–F). (A) 0.1 lM HCoV 229E M
pro solution with
10 lM substrate.
(B) 0.1 lM TGEV M
pro solution with 20 lM substrate.
(C) 0.05 lM FIPV M
pro solution with 10 lM substrate.
(D) 0.6 lM MHV M
pro solution with 20 lM substrate.
(E) 0.8 lM IBV M
pro solution with 20 lM substrate.
(F) 1 lM SARS-CoV M
pro solution with 20 lM substrate.
(G) The preliminary inhibitory assay of N3 on M
pro of a newly
identiﬁed CoV (HCoV-HKU1). Curve A represents the activity curve
of 1 lMM
pro of HCoV-HKU1 in cleaving 20 lM substrate with time;
curves B and C individually represent the decrease in enzyme activity
when N3 was added with 2-fold and 4-fold molar of protease.
(H) The preliminary inhibitory assay of N3 on M
pro of a recently
identiﬁed CoV (HCoV-NL63). Curve A represents the activity curve
of 0.5 lMM
pro of HCoV-NL63 in cleaving 10 lM substrate with time;
curves B and C individually represent the decrease in enzyme activity
when N3 was added with 2-fold and 4-fold molar of protease.
Found at DOI: 10.1371/journal.pbio.0030324.sg002 (1.2 MB PDF).
Figure S3. The Cytotoxicity of N3 on Murine DBT Cells
Found at DOI: 10.1371/journal.pbio.0030324.sg003 (124 KB PDF).
Table S1. Data Collection and Reﬁnement Statistics
Found at DOI: 10.1371/journal.pbio.0030324.st001 (120 KB PDF).
Table S2. Representative Inhibitors Designed in the First Round (I2
not shown here)
Found at DOI: 10.1371/journal.pbio.0030324.st002 (128 KB PDF).
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prosTable S3. Representative Inhibitors Designed in the Second Round
(N1 and N3 not shown here)
Found at DOI: 10.1371/journal.pbio.0030324.st003 (121 KB PDF).
Protocol S1.
Found at DOI: 10.1371/journal.pbio.0030324.sd001 (137 KB PDF).
Accession Numbers.
The Protien Data Bank (http://www.rcsb.org/pdb/) accession numbers
for the structures of SARS M
pro individually complexed with I2, N1,
N3, and, N9, and TEGV M
pro in complex with N1 are 1WNQ, 1WOF,
2AMQ, 2AMD, and 2AMP, respectively. The GenBank (http://www.
ncbi.nih.gov/Genbank/) accession number for IBV M
pro is DQ157446.
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Note Added in Proof
The version of this paper that was ﬁrst made available on 6 September 2005
has been replaced by this, the deﬁnitive, version: there was a typesetting error
in equation 1 that has now been corrected.
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